Evereklioglu Cem, Turkoz Yusuf, Calis Mustafa, Duygulu Fuat, Karabulut Aysun B
Department of Ophthalmology Erciyes University Medical Faculty, Kayseri, Turkey.
Mediators Inflamm. 2004 Jun;13(3):165-70. doi: 10.1080/09511920410001713547.
Weill-Marchesani syndrome (WMS) is a rare systemic disorder with both autosomal recessive and dominant inheritances. Accumulation of reactive oxygen species such as O2*-, H2O2 and OH* causes lipid peroxidation (LPO), whereas antioxidant enzymes (superoxide dismutase (SOD), glutathione peroxidase (GSHPx)) mediate defence against oxidative stress. Excess tumour necrosis factor (TNF)-alpha and NO* react with O2*- and cause further antioxidant depletion with an increase in mutation frequency by H2O2. This study investigated the levels of SOD, GSHPx, catalase (CAT), TNF-alpha, NO and LPO in patients with WMS.
A group of 10 WMS patients (four males, six females; age, 26.5+/-19.0 years) and 10 age-matched and sex-matched controls (five males, five females; age, 27.3+/-18.2 years) were included. Serum TNF-alpha levels were determined by a spectrophotometer technique using immulite chemiluminescent immunometric assay. Malondialdehyde (MDA) was determined in plasma; CAT in red blood cells (RBCs), and SOD and GSHPx in both plasma and RBCs. Total serum NO* levels were evaluated by Griess reaction.
Mean levels of TNF-alpha (8.3+/-0.6 pg/ml) in WMS patients were significantly (p<0.001) higher than controls (4.3+/-0.2 pg/ml). Plasma MDA levels in patients and controls were 5.4+/-0.8 and 1.8+/-0.6 micromol/l, respectively, and the difference was significant (p=0.0002). SOD and GSHPx activities were significantly lower in both RBCs and plasma of WMS than in controls (RBC-SOD, 3981.9+/-626.6 versus 5261.6+/-523.0 U/g haemoglobin (Hb), p=0.0005; plasma-SOD, 529.4+/-49.3 versus 713.4+/-55.7 U/g protein, p=0.0002; RBC-GSHPx, 682.7+/-42.0 versus 756.5+/-47.6 U/g Hb, p=0.0011; plasma-GSHPx, 107.3+/-15.0 versus 131.4+/-19.7 U/g protein, p=0.0113). In addition, serum NO (NO*-2 + NO*-3) levels were also significantly (p = 0.0002) increased in WMS patients (54.4+/-5.7 versus 26.9+/-6.7 micromol/l). RBC-CAT levels were similar between groups (125.6+/-21.3 versus 131.0+/-21.5 k/g Hb, p = 0.8798).
The elevated LPO, TNF-alpha and NO* with decreased antioxidant enzyme activities indicated impaired antioxidative defence mechanisms with an oxidative injury and cell toxicity in WMS patients. The use of multiple antioxidants and free radical scavengers might be helpful in this genetic disorder.
韦尔-马切萨尼综合征(WMS)是一种罕见的具有常染色体隐性和显性遗传的全身性疾病。活性氧如超氧阴离子(O2*-)、过氧化氢(H2O2)和羟自由基(OH*)的积累会导致脂质过氧化(LPO),而抗氧化酶(超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSHPx))介导对氧化应激的防御。过量的肿瘤坏死因子(TNF)-α和一氧化氮(NO*)与超氧阴离子反应,并通过过氧化氢导致进一步的抗氧化剂消耗,同时增加突变频率。本研究调查了WMS患者中超氧化物歧化酶、谷胱甘肽过氧化物酶、过氧化氢酶(CAT)、肿瘤坏死因子-α、一氧化氮和脂质过氧化的水平。
纳入一组10例WMS患者(4例男性,6例女性;年龄,26.5±19.0岁)和10例年龄和性别匹配的对照(5例男性,5例女性;年龄,27.3±18.2岁)。采用免疫发光化学免疫分析法通过分光光度计技术测定血清肿瘤坏死因子-α水平。测定血浆中的丙二醛(MDA);红细胞(RBC)中的过氧化氢酶,以及血浆和红细胞中的超氧化物歧化酶和谷胱甘肽过氧化物酶。通过格里斯反应评估血清总一氧化氮水平。
WMS患者中肿瘤坏死因子-α的平均水平(8.3±0.6 pg/ml)显著高于对照组(4.3±0.2 pg/ml)(p<0.001)。患者和对照组的血浆丙二醛水平分别为5.4±0.8和1.8±0.6 μmol/l,差异显著(p = 0.00)。WMS患者红细胞和血浆中的超氧化物歧化酶和谷胱甘肽过氧化物酶活性均显著低于对照组(红细胞超氧化物歧化酶,3981.9±626.6对5261.6±523.0 U/g血红蛋白(Hb),p = 0.0005;血浆超氧化物歧化酶,529.4±49.3对713.4±55.7 U/g蛋白,p = 0.0002;红细胞谷胱甘肽过氧化物酶,682.7±42.0对756.5±47.6 U/g Hb,p = 0.0011;血浆谷胱甘肽过氧化物酶,107.3±15.0对131.4±19.7 U/g蛋白,p = 0.0113)。此外,WMS患者的血清一氧化氮(NO*-2 + NO*-3)水平也显著升高(p = 0.0002)(54.4±5.7对26.9±6.7 μmol/l)。两组间红细胞过氧化氢酶水平相似(125.6±21.3对131.0±21.5 k/g Hb,p = 0.8798)。
脂质过氧化、肿瘤坏死因子-α和一氧化氮升高以及抗氧化酶活性降低表明WMS患者的抗氧化防御机制受损,存在氧化损伤和细胞毒性。使用多种抗氧化剂和自由基清除剂可能对这种遗传性疾病有帮助。